KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) FCF Margin (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed FCF Margin for 16 consecutive years, with 127.42% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin rose 14040.0% year-over-year to 127.42%, compared with a TTM value of 74.96% through Sep 2025, up 31350.0%, and an annual FY2024 reading of 66.44%, up 183917.0% over the prior year.
  • FCF Margin was 127.42% for Q3 2025 at TherapeuticsMD, up from 40.02% in the prior quarter.
  • Across five years, FCF Margin topped out at 5004.52% in Q3 2022 and bottomed at 11373.58% in Q3 2023.
  • Average FCF Margin over 5 years is 966.12%, with a median of 73.16% recorded in 2024.
  • The sharpest move saw FCF Margin plummeted -1637810bps in 2023, then soared 1136061bps in 2024.
  • Year by year, FCF Margin stood at 73.06% in 2021, then surged by 160bps to 44.1% in 2022, then tumbled by -2341bps to 988.05% in 2023, then soared by 100bps to 2.55% in 2024, then skyrocketed by 4899bps to 127.42% in 2025.
  • Business Quant data shows FCF Margin for TXMD at 127.42% in Q3 2025, 40.02% in Q2 2025, and 177.86% in Q1 2025.